Landos Biopharma, Inc.
landosbiopharma.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q1 FY2024 10-Q, filed May 9, 2024. Its latest SEC filing is a 15-12G from Jun 3, 2024.
10-Q for Q1 FY2024, filed May 9, 2024
The sections below describe the company as of the FY2023 annual report.
What Did They Do?
Develops oral drug candidates for autoimmune diseases, including potential treatments for ulcerative colitis, Crohn’s disease and other inflammatory conditions.
10-K for FY2023, filed Mar 21, 2024We are a clinical-stage biopharmaceutical company focused on the development of novel, oral, once-daily therapeutics for patients with…View ↗
Our current focus and lead product candidate is NX-13, a novel, oral, gut-selective, NLRX1 agonist. We are developing NX-13 as a…View ↗
In addition to NX-13, we have several preclinical product candidates, including the following:View ↗
Who Were Their Customers?
Lian is the customer under an exclusive licensing and collaboration agreement, with rights to develop, manufacture and commercialize NX-13 in specified Asian markets.
10-K for FY2023, filed Mar 21, 2024
How Were They Changing?
- Net income
-
Sources
10-Q for Q1 FY2024, filed May 9, 2024
−$8.9MView ↗
- ▲ +47% (Loss)
- vs −$6M in Q1 FY2023
-
May 23, 2024
AbbVie completed its acquisition of Landos
Landos became a wholly owned subsidiary of Parent.
Sources
8-K, filed May 23, 2024
As described in the Introductory Note, on May 23, 2024, the Merger was completed. Upon the consummation of the Merger, the Company became a…View ↗
-
Mar 25, 2024
Landos agreed to be acquired by AbbVie
The agreement offered cash per share plus a contingent value right tied to a clinical development milestone.
Sources
8-K, filed Mar 25, 2024
On March 24, 2024, Landos Biopharma, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Bespin…View ↗
Who Did They Compete With?
Competes with AbbVie, Amgen, Boehringer Ingelheim, Eli Lilly, Janssen Pharmaceuticals, Pfizer, Roche Holding, Sanofi, Teva Pharmaceutical Industries, Takeda Pharmaceutical, UCB, Abivax, Bristol-Myers Squibb, Galapagos, Gilead Sciences, Merck, Morphic Therapeutics, Protagonist Therapeutics, Reistone Biopharma, and Roivant Sciences
10-K for FY2023, filed Mar 21, 2024We are aware of several other products and product candidates as potential treatments for UC that would compete with NX-13, if approved. In…View ↗
Loading...
